Can atherogenic indices and the triglyceride-glucose index be used to predict erectile dysfunction?
Özet
Background: Atherosclerosis and insulin resistance play an important role in the development of erectile dysfunction (ED), and few studies have comprehensively evaluated more specific indicators like atherogenic indices and the triglyceride-glucose (TyG) index in the assessment of ED. Aim: This study aimed to reveal the role of atherogenic indices (atherogenic index of plasma [AIP], Castelli risk index-1/2 [CRI-1/2], and atherogenic coefficient [AC]) based on plasma lipid ratios, which have been used as more sensitive indicators of atherosclerosis in recent years, and the TyG index, a practical indicator of insulin resistance, in predicting vasculogenic ED. Methods: The study included a total of 199 patients who met the inclusion criteria and a total of 51 control subjects without ED complaints according to the International Index of Erectile Function (IIEF-5) scores (>21) between May 2021 and October 2022. For all participants, the demographic and biochemical parameters were evaluated, and atherogenic indices, namely CRI-1 (total cholesterol/high-density lipoprotein [HDL]), CRI-2 (LDL/HDL) AIP [log10(triglycerides/HDL)], and AC (non-HDL/HDL), as well as the TyG index [Ln {fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2}] were calculated. Outcomes: The TyG index, which is an indicator of insulin resistance, and atherogenic indices such as CRI-1, AIP, and AC were significantly associated with ED, and especially AIP and the TyG index seem to be more important in the evaluation of ED. Results: According to the univariate analysis, the patient group had significantly higher CRI-1 (5.3 ± 1.4 vs 4.7 ± 1.3; P = .005), AIP (0.31 ± 0.26 vs 0.13 ± 0.2; P < .001), AC (4.1 ± 1.4 vs 3.70 ± 1.2; P = .026), and TyG (9.16 ± 0.71 vs 8.77 ± 0.52; P < .001) values compared with the control group. In the correlation analysis, a significant negative correlation was found between the AIP and TyG index and the IIEF-5 scores (r2 = 0.120, P < .001 between AIP and IIEF-5; r2 = 0.091, P < .001 between TyG index and IIEF-5). The multivariate analysis revealed AIP and the TyG index as independent predictive factors for ED. Clinical Implications: The use of atherogenic indices and TyG index in daily urology practice can help physicians in the diagnosis and follow-up of ED. Strengths and Limitations: The lack of sex hormone–binding globulin and free testosterone levels represents a limitation of our study. Another limitation is that the severity of ED was determined using the IIEF-5 scores, rather than a more objective method, such as penile artery ultrasound. Conclusion: Atherogenic indices and the TyG index can be used as inexpensive and practical markers to predict the severity of arteriogenic ED. © 2023 Elsevier B.V.. All rights reserved.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Sambel, Murat | |
| dc.contributor.author | Erdogan, Abdullah | |
| dc.contributor.author | Caglayan, Volkan | |
| dc.contributor.author | Avci, Sinan | |
| dc.contributor.author | Kilic, Sahin | |
| dc.contributor.author | Yildiz, Halil Emre | |
| dc.contributor.author | Keskin, Ercument | |
| dc.date.accessioned | 2026-10-18T20:27:00.362488927Z | |
| dc.date.available | 2026-10-18T20:27:00.362488927Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Background: Atherosclerosis and insulin resistance play an important role in the development of erectile dysfunction (ED), and few studies have comprehensively evaluated more specific indicators like atherogenic indices and the triglyceride-glucose (TyG) index in the assessment of ED. Aim: This study aimed to reveal the role of atherogenic indices (atherogenic index of plasma [AIP], Castelli risk index-1/2 [CRI-1/2], and atherogenic coefficient [AC]) based on plasma lipid ratios, which have been used as more sensitive indicators of atherosclerosis in recent years, and the TyG index, a practical indicator of insulin resistance, in predicting vasculogenic ED. Methods: The study included a total of 199 patients who met the inclusion criteria and a total of 51 control subjects without ED complaints according to the International Index of Erectile Function (IIEF-5) scores (>21) between May 2021 and October 2022. For all participants, the demographic and biochemical parameters were evaluated, and atherogenic indices, namely CRI-1 (total cholesterol/high-density lipoprotein [HDL]), CRI-2 (LDL/HDL) AIP [log10(triglycerides/HDL)], and AC (non-HDL/HDL), as well as the TyG index [Ln {fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2}] were calculated. Outcomes: The TyG index, which is an indicator of insulin resistance, and atherogenic indices such as CRI-1, AIP, and AC were significantly associated with ED, and especially AIP and the TyG index seem to be more important in the evaluation of ED. Results: According to the univariate analysis, the patient group had significantly higher CRI-1 (5.3 ± 1.4 vs 4.7 ± 1.3; P = .005), AIP (0.31 ± 0.26 vs 0.13 ± 0.2; P < .001), AC (4.1 ± 1.4 vs 3.70 ± 1.2; P = .026), and TyG (9.16 ± 0.71 vs 8.77 ± 0.52; P < .001) values compared with the control group. In the correlation analysis, a significant negative correlation was found between the AIP and TyG index and the IIEF-5 scores (r2 = 0.120, P < .001 between AIP and IIEF-5; r2 = 0.091, P < .001 between TyG index and IIEF-5). The multivariate analysis revealed AIP and the TyG index as independent predictive factors for ED. Clinical Implications: The use of atherogenic indices and TyG index in daily urology practice can help physicians in the diagnosis and follow-up of ED. Strengths and Limitations: The lack of sex hormone–binding globulin and free testosterone levels represents a limitation of our study. Another limitation is that the severity of ED was determined using the IIEF-5 scores, rather than a more objective method, such as penile artery ultrasound. Conclusion: Atherogenic indices and the TyG index can be used as inexpensive and practical markers to predict the severity of arteriogenic ED. © 2023 Elsevier B.V.. All rights reserved. | |
| dc.identifier.doi | 10.1093/sexmed/qfad069 | |
| dc.identifier.eissn | 2050-1161 | |
| dc.identifier.issn | 2050-1161 | |
| dc.identifier.issue | 6 | |
| dc.identifier.pmcid | PMC10799712 | |
| dc.identifier.pmid | 38250336 | |
| dc.identifier.scopus | 2-s2.0-85196263037 | |
| dc.identifier.startpage | qfad069 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/12052 | |
| dc.identifier.volume | 11 | |
| dc.identifier.wos | WOS:001155037800002 | |
| dc.language.iso | en | |
| dc.publisher | Oxford University Press | |
| dc.relation.ispartof | Sexual Medicine | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | atherogenic indices | |
| dc.subject | endothelial dysfunction | |
| dc.subject | erectile dysfunction | |
| dc.subject | insulin resistance | |
| dc.subject | triglyceride-glucose index | |
| dc.subject | glucose | |
| dc.subject | high density lipoprotein | |
| dc.subject | low density lipoprotein | |
| dc.subject | sex hormone binding globulin | |
| dc.subject | testosterone | |
| dc.subject | triacylglycerol | |
| dc.subject | adult | |
| dc.subject | Article | |
| dc.subject | atherogenic index | |
| dc.subject | cholesterol blood level | |
| dc.subject | comparative study | |
| dc.subject | controlled study | |
| dc.subject | correlation analysis | |
| dc.subject | cross-sectional study | |
| dc.subject | follow up | |
| dc.subject | human | |
| dc.subject | International Index of Erectile Function | |
| dc.subject | lipid blood level | |
| dc.subject | major clinical study | |
| dc.subject | male | |
| dc.subject | middle aged | |
| dc.subject | penis artery | |
| dc.title | Can atherogenic indices and the triglyceride-glucose index be used to predict erectile dysfunction? | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 10 | |
| rdl.citation.wos | 9 | |
| rdl.department | Department of Urology, Mengucek Gazi Education and Research Hospital, Erzincan Binali Yildirim University, 24002, Erzincan, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
